Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.

Abstract

Pituitary neuroendocrine tumors (PitNET) are commonly benign tumors accounting for 10-25% of intracranial tumors. Prolactin-secreting adenomas represent the most predominant type of all PitNET and for this subtype of tumors, the medical therapy relies on the use of dopamine agonists (DAs). DAs yield an excellent therapeutic response in reducing tumor size and hormonal secretion targeting the dopamine receptor type 2 (D2DR) whose higher expression in prolactin-secreting adenomas compared to other PitNET is now well established. Moreover, although DAs therapy does not represent the first-line therapy for other PitNET, off-label use of DAs is considered in PitNET expressing D2DR. Nevertheless, DAs primary or secondary resistance, occurring in a subset of patients, may involve several molecular mechanisms, presently not fully elucidated. Dopamine receptors (DRs) expression is a prerequisite for a proper DA function in PitNET and several molecular events may negatively modify DR membrane expression, through the DRs down-regulation and intracellular trafficking, and DR signal transduction pathway. The current mini-review will summarise the presently known molecular events that underpin the unsuccessful therapy with DAs.

• Authors: Claudia Pivonello, Roberta Patalano, Mariarosaria Negri, Rosa Pirchio, Annamaria Colao, Rosario Pivonello, Renata Simona Auriemma
• Journal: Frontiers in endocrinology (Front Endocrinol (Lausanne)) Vol. 12 Pg. 791633 ( 2021) ISSN: 1664-2392 [Print] Switzerland
• PMID: 35095761 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2022 Pivonello, Patalano, Negri, Pirchio, Colao, Pivonello and Auriemma.

Chemical References

• Aminoquinolines
• Dopamine Agonists
• Filamins
• MicroRNAs
• Receptors, Dopamine D2
• beta-Arrestins
• Pergolide
• Bromocriptine
• quinagolide
• Lisuride
• Cabergoline

Topics

• ACTH-Secreting Pituitary Adenoma (drug therapy, metabolism)
• Adenoma (drug therapy, metabolism)
• Aminoquinolines (therapeutic use)
• Bromocriptine (therapeutic use)
• Cabergoline (therapeutic use)
• Dopamine Agonists (therapeutic use)
• Drug Resistance, Neoplasm
• Filamins (metabolism)
• Growth Hormone-Secreting Pituitary Adenoma (drug therapy, metabolism)
• Humans
• Lisuride (therapeutic use)
• MicroRNAs (metabolism)
• Pergolide (therapeutic use)
• Pituitary Neoplasms (drug therapy, metabolism)
• Prolactinoma (drug therapy, metabolism)
• Receptors, Dopamine D2 (agonists, metabolism)
• beta-Arrestins (metabolism)